Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis.

ABSTRACT:

Objectives

Both telitacicept and belimumab are approved for treating active systemic lupus erythematosus (SLE) in China. However, the economic value of these two drugs is unclear. Therefore, this study aims to evaluate the cost-effectiveness of telitacicept versus belimumab in SLE from the perspective of Chinese society.

Methods

The network meta-analysis (NMA) and cost-effectiveness analysis included the efficacy and safety of patients from five randomised clinical trials. A microsimulation model was constructed to compare the cost-effectiveness of telitacicept versus belimumab in SLE. The model integrated short-term efficacy and long-term prognosis to simulate the patient's lifetime. Outcome measures included life years (LYs), quality-adjusted LYs (QALYs), total healthcare

SUBMITTER: Deng L 

PROVIDER: S-EPMC12820815 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature